OSE 2101 regulatory update

Orphan Synergy Europe-Pharma said FDA granted Orphan Drug designation for OSE 2101 to treat non-small cell lung cancer (NSCLC) in HLA-A2-positive patients. A Phase II trial of OSE 2101 in severe NSCLC...